Loading institutional data...
Loading institutional data...
Strong institutional accumulation: ownership increased +4.79% quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$68M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A cash-return story — far more went to shareholders than back into the business (mature, low-reinvestment).
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: -31%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $34M covers the $11M due within a year 3.1× over. Scheduled principal only (excludes interest & revolver draws). As of 2019-12-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~5.7% on $49M of debt. Interest last disclosed in FY2022 (no longer broken out).
Cash of $34M fully covers short-term debt of $5M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
Nothing notable to watch.
Where each multiple sits in its own 14-yr range · 74th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 3.9 | 1.0 | 8.0 | 0.0 | 0.0 | 7.1 | 2.0 | 0.6 |
| R&D | 158.6 | 28.5 | 640.2 | 18471.8 | 37997.1 | 4890.9 | 271.8 | 122.7 |
| SG&A | 100.9 | 17.6 | 196.8 | 10853.0 | 34592.1 | 9466.9 | 460.4 | 74.9 |
| Operating Income | -163.4 | 43.9 | -199.2 | -29224.8 | -72489.2 | -14265.0 | -634.2 | -98.2 |
| Income Tax | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Income | -190.7 | 40.4 | -244.1 | -29449.0 | -73341.0 | -14710.9 | -644.8 | -101.1 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on LXRX: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $49.8M 100.0% | $31.1M 100.0% | $1.2M 100.0% | $139K 100.0% | $298K 100.0% | $24.0M 100.0% | $322.1M 100.0% | $63.2M 100.0% | $91.7M 100.0% | $79.3M 100.0% |
| Cost of Revenue | $274K 0.6% | $616K 2.0% | $85K 7.1% | $0 0.0% | $0 0.0% | $1.9M 8.0% | $3.2M 1.0% | $2.5M 3.9% | $1.9M 2.1% | $0 0.0% |
| Cost of Products | — | — | — | — | — | — | — | — | $1.9M 2.1% | $0 0.0% |
| Research & Development | $61.1M 122.7% | $84.5M 271.8% | $58.9M 4890.9% | $52.8M 37997.1% | $55.0M 18471.8% | $153.6M 640.2% | $91.9M 28.5% | $100.2M 158.6% | $152.2M 166.0% | $164.0M 206.9% |
| Selling, General & Admin | $37.3M 74.9% | $143.1M 460.4% | $114.0M 9466.9% | $48.1M 34592.1% | $32.3M 10853.0% | $47.2M 196.8% | $56.8M 17.6% | $63.8M 100.9% | $66.1M 72.1% | $43.2M 54.5% |
| Total Operating Expenses | $98.7M 198.2% | $228.2M 734.2% | $173.0M 14365.0% | $100.9M 72589.2% | $87.4M 29324.8% | $204.4M 851.8% | $180.6M 56.1% | $166.5M 263.4% | $222.3M 242.5% | $206.4M 260.5% |
| Operating Income | -$48.9M -98.2% | -$197.1M -634.2% | -$171.8M -14265.0% | -$100.8M -72489.2% | -$87.1M -29224.8% | -$47.8M -199.2% | $141.4M 43.9% | -$103.3M -163.4% | -$130.6M -142.5% | -$127.2M -160.5% |
| Interest Expense | — | — | — | $2.8M 2000.0% | $802K 269.1% | $14.5M 60.6% | $20.7M 6.4% | $20.8M 32.9% | $7.0M 7.6% | $6.6M 8.3% |
| Other Income (Expense), net | $6.9M 13.9% | $12.3M 39.6% | $7.7M 642.2% | $1.6M 1148.2% | $134K 45.0% | $2.8M 11.5% | $3.4M 1.0% | $3.5M 5.5% | $2.0M 2.1% | $2.3M 2.9% |
| Pretax Income | — | — | — | — | -$87.8M -29449.0% | -$58.6M -244.1% | $124.1M 38.5% | -$120.5M -190.7% | -$135.7M -148.0% | -$131.4M -165.8% |
| Income Tax Expense | — | $0 0.0% | $0 0.0% | $0 0.0% | $0 0.0% | — | — | — | — | $0 0.0% |
| Net Income | -$50.3M -101.1% | -$200.4M -644.8% | -$177.1M -14710.9% | -$101.9M -73341.0% | -$87.8M -29449.0% | -$58.6M -244.1% | $130.1M 40.4% | -$120.5M -190.7% | -$123.0M -134.1% | -$131.4M -165.8% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.23 | $-1.14 | $-1.17 | — |
| EPS (Diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | — |
| Weighted Avg Shares (Basic) | 363.1M | 320.0M | 221.1M | 165.7M | 145.7M | — | — | — | — | — |
| Weighted Avg Shares (Diluted) | 363.1M | 320.0M | 221.1M | 165.7M | 145.7M | 110.8M | 116.7M | 105.8M | 105.2M | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.24T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.03T | 50.2× | — | 15.9× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $894.1B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $650.5B | 24.5× | — | 6.9× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $467.1B | 111.9× | 33.4× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $368.2B | 20.2× | — | 5.7× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $339.9B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $257.7B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $248.2B | 37.1× | 31.9× | 5.6× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $204.6B | 26.7× | 17.6× | 5.6× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $187.3B | 22.3× | 20.4× | 6.4× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.0B | 27.5× | 19.2× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $157.1B | 20.3× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $150.2B | 42.1× | 31.0× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $136.2B | 48.7× | 37.5× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $131.1B | 33.7× | 28.8× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $127.8B | 18.2× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.8B | 24.9× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| CVS | $114.7B | 64.9× | 11.5× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $107.1B | 33.4× | 18.4× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $102.5B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.4B | 15.1× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.4B | 16.4× | 15.5× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $82.6B | 19.0× | 19.8× | 5.8× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
| CI | $72.7B | 12.4× | 5.5× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 14.1% | 0.0× | 1,583 |
| LXRX | $746M | — | — | 15.0× | 60.2% | 99.4% | -101% | -46.8% | -31.2% | -1.1× | 134 |
Peers = companies sharing LXRX's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position